Clinical Trial

QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-23.
Status change: Not Yet Recruiting → Recruiting 2026-01-22
Trial Details
NCT Number NCT06951997
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions Metastatic Pancreatic Cancer
Enrollment 33 participants
Start Date 2025-03-07
Primary Completion 2027-05-15 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-26